Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2015 (2015), Article ID 901046, 7 pages
http://dx.doi.org/10.1155/2015/901046
Review Article

Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies

1Nightingale and Genesis Prevention Centre, University Hospital South Manchester, Southmoor Road, Manchester M23 9LT, UK
2Department of Breast Surgery, Queen Elizabeth Hospital, Birmingham B15 2TH, UK
3The Institute of Cancer Sciences, The University of Manchester, Oxford Road, Manchester M13 9PL, UK
4University of Manchester Department of Genomic Medicine, Institute of Human Development, St. Mary’s Hospital, Oxford Road, Manchester M13 9WL, UK

Received 20 August 2014; Revised 2 January 2015; Accepted 9 January 2015

Academic Editor: Kazuhiro Yoshida

Copyright © 2015 N. N. Basu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, P. Pisani, and J. Ferlay, “Estimates of the worldwide mortality from 25 cancers in 1990,” International Journal of Cancer, vol. 83, no. 1, pp. 18–29, 1999. View at Google Scholar
  2. World Cancer Research Fund International, Breast Cancer Statistics, 2012, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics.
  3. Cancer Research UK, 2014, http://cancerresearchuk.org/cancer.
  4. I. M. Lizarraga, S. L. Sugg, R. J. Weigel, and C. E. H. Scott-Conner, “Review of risk factors for the development of contralateral breast cancer,” The American Journal of Surgery, vol. 206, no. 5, pp. 704–708, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. T. M. Tuttle, E. B. Habermann, E. H. Grund, T. J. Morris, and B. A. Virnig, “Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5203–5209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Güth, M. E. Myrick, C. T. Viehl, W. P. Weber, A. M. Lardi, and S. M. Schmid, “Increasing rates of contralateral prophylactic mastectomy—a trend made in USA?” European Journal of Surgical Oncology, vol. 38, no. 4, pp. 296–301, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Vichapat, C. Gillett, I. S. Fentiman, A. Tutt, L. Holmberg, and M. Lüchtenborg, “Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways,” European Journal of Cancer, vol. 47, no. 13, pp. 1919–1927, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Metcalfe, H. T. Lynch, P. Ghadirian et al., “Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2328–2335, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. D. G. R. Evans, A. Moran, R. Hartley et al., “Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status,” British Journal of Cancer, vol. 102, no. 7, pp. 1091–1098, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Metcalfe, S. Gershman, H. T. Lynch et al., “Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers,” British Journal of Cancer, vol. 104, no. 9, pp. 1384–1392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. K. Graeser, C. Engel, K. Rhiem et al., “Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5887–5892, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Ford, D. F. Easton, M. Stratton et al., “Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families,” The American Journal of Human Genetics, vol. 62, no. 3, pp. 676–689, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. D. G. Evans, A. Shenton, E. Woodward, F. Lalloo, A. Howell, and E. R. Maher, “Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family,” BMC cancer, vol. 8, article 155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Lalloo and D. G. Evans, “Familial breast cancer,” Clinical Genetics, vol. 82, no. 2, pp. 105–114, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Thompson and D. F. Easton, “Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers,” Journal of the National Cancer Institute, vol. 94, no. 18, pp. 1358–1365, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Mavaddat, S. Peock, D. Frost et al., “Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE,” Journal of the National Cancer Institute, vol. 105, no. 11, pp. 812–822, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Gronwald, A. Robidoux, C. Kim-Sing et al., “Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers,” Breast Cancer Research and Treatment, vol. 146, no. 2, pp. 421–427, 2014. View at Publisher · View at Google Scholar
  18. A. Chompret, L. Brugières, M. Ronsin et al., “P53 germline mutations in childhood cancers and cancer risk for carrier individuals,” British Journal of Cancer, vol. 82, no. 12, pp. 1932–1937, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Masciari, D. A. Dillon, M. Rath et al., “Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort,” Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 1125–1130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Reiner, E. M. John, J. D. Brooks et al., “Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women’s environmental cancer and radiation epidemiology study,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 433–439, 2013. View at Publisher · View at Google Scholar
  21. S. K. McDonnell, D. J. Schaid, J. L. Myers et al., “Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer,” Journal of Clinical Oncology, vol. 19, no. 19, pp. 3938–3943, 2001. View at Google Scholar · View at Scopus
  22. A. K. Arrington, S. L. Jarosek, B. A. Virnig, E. B. Habermann, and T. M. Tuttle, “Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer,” Annals of Surgical Oncology, vol. 16, no. 10, pp. 2697–2704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. L. Bernstein, R. H. Lapinski, S. S. Thakore, J. T. Doucette, and W. D. Thompson, “The descriptive epidemiology of second primary breast cancer,” Epidemiology, vol. 14, no. 5, pp. 552–558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Mitri, T. Constantine, and R. O'Regan, “The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy,” Chemotherapy Research and Practice, vol. 2012, Article ID 743193, 7 pages, 2012. View at Publisher · View at Google Scholar
  25. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Gianni, U. Dafni, R. D. Gelber et al., “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial,” The Lancet Oncology, vol. 12, no. 3, pp. 236–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. B. S. Saltzman, K. E. Malone, J. A. McDougall, J. R. Daling, and C. I. Li, “Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer,” Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 849–855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Cuzick, I. Sestak, J. F. Forbes et al., “Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial,” The Lancet, vol. 383, no. 9922, pp. 1041–1048, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Cuzick, I. Sestak, M. Baum et al., “Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial,” The Lancet Oncology, vol. 11, no. 12, pp. 1135–1141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005. View at Publisher · View at Google Scholar
  31. J. L. Bernstein, D. C. Thomas, R. E. Shore et al., “Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE Study Report,” European Journal of Cancer, vol. 49, no. 14, pp. 2979–2985, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Plummer, “Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?” Breast Cancer Research, vol. 13, no. 4, article 218, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Tutt, M. Robson, J. E. Garber et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial,” The Lancet, vol. 376, no. 9737, pp. 235–244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. N. N. Basu, L. Barr, D. G. Evans, and G. L. Ross, “Threshold for genetic testing in women with breast cancer needs to be determined,” British Medical Journal, vol. 348, Article ID g1863, 2014. View at Publisher · View at Google Scholar
  35. D. G. Evans, J. Barwell, D. M. Eccles et al., “The Angelina Jolie effect: how high celebrity profile can have a major effect on provision of cancer related services,” Breast Cancer Research, vol. 16, no. 5, article 442, 2014. View at Google Scholar
  36. S. M. Domchek, T. M. Friebel, C. F. Singer et al., “Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality,” JAMA—Journal of the American Medical Association, vol. 304, no. 9, pp. 967–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Lostumbo, N. E. Carbine, and J. Wallace, “Prophylactic mastectomy for the prevention of breast cancer,” Cochrane Database of Systematic Reviews, vol. 11, Article ID CD002748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Metcalfe, S. Gershman, P. Ghadirian et al., “Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis,” British Medical Journal, vol. 348, article g226, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. D. G. R. Evans, S. L. Ingham, A. Baildam et al., “Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer,” Breast Cancer Research and Treatment, vol. 140, no. 1, pp. 135–142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. T. C. van Sprundel, M. K. Schmidt, M. A. Rookus et al., “Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers,” British Journal of Cancer, vol. 93, no. 3, pp. 287–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. B. Zeichner, A. L. Ruiz, N. J. Markward, and E. Rodriguez, “Improved long-term survival with contralateral prophylactic mastectomy among young women,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 3, pp. 1155–1162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Bedrosian, C. Y. Hu, and G. J. Chang, “Population-based study of mastectomy and survival outcomes of breast cancer patients,” Journal of the National Cancer Institute, vol. 102, no. 6, pp. 401–409, 2010. View at Google Scholar
  43. P. R. Portschy, K. M. Kuntz, and T. M. Tuttle, “Survival outcomes after contralateral prophylactic mastectomy: a decision analysis,” Journal of the National Cancer Institute, vol. 106, no. 8, Article ID dju160, 2014. View at Publisher · View at Google Scholar
  44. T. A. King, R. Sakr, S. Patil et al., “Clinical management factors contribute to the decision for contralateral prophylactic mastectomy,” Journal of Clinical Oncology, vol. 29, no. 16, pp. 2158–2164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Ashfaq, L. J. McGhan, B. A. Pockaj et al., “Impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy,” Annals of Surgical Oncology, vol. 21, no. 9, pp. 2934–2940, 2014. View at Publisher · View at Google Scholar
  46. M. E. Miller, T. Czechura, B. Martz et al., “Operative risks associated with contralateral prophylactic mastectomy: a single institution experience,” Annals of Surgical Oncology, vol. 20, no. 13, pp. 4113–4120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. M. A. Crosby, P. B. Garvey, J. C. Selber et al., “Reconstructive outcomes in patients undergoing contralateral prophylactic mastectomy,” Plastic and Reconstructive Surgery, vol. 128, no. 5, pp. 1025–1033, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. W.-B. Zhou, X.-A. Liu, J.-C. Dai, and S. Wang, “Meta-analysis of sentinel lymph node biopsy at the time of prophylactic mastectomy of the breast,” Canadian Journal of Surgery, vol. 54, no. 5, pp. 300–306, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. R. E. Mansel, L. Fallowfield, M. Kissin et al., “Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial,” Journal of the National Cancer Institute, vol. 98, no. 9, pp. 599–609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. N. K. Kuwajerwala, N. S. Dekhne, P. A. Pentiak et al., “Sentinel lymph node biopsy in contralateral prophylactic mastectomy: are we overtreating? Experience at a tertiary care hospital,” Clinical Breast Cancer, vol. 13, no. 4, pp. 287–291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. V. R. Grann, P. R. Patel, J. S. Jacobson et al., “Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers,” Breast Cancer Research and Treatment, vol. 125, no. 3, pp. 837–847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Schrag, K. M. Kuntz, J. E. Garber, and J. C. Weeks, “Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations,” Journal of the American Medical Association, vol. 283, no. 5, pp. 617–624, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Zendejas, J. P. Moriarty, J. O'Byrne, A. C. Degnim, D. R. Farley, and J. C. Boughey, “Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer,” Journal of Clinical Oncology, vol. 29, no. 22, pp. 2993–3000, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. A. A. Deshmukh, S. B. Cantor, M. A. Crosby et al., “Cost of contralateral prophylactic mastectomy,” Annals of Surgical Oncology, vol. 21, no. 9, pp. 2823–2830, 2014. View at Publisher · View at Google Scholar
  55. A. Roberts, M. Habibi, and K. D. Frick, “Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer,” Annals of Surgical Oncology, vol. 21, no. 7, pp. 2209–2217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. S. T. Hawley, R. Jagsi, M. Morrow et al., “Social and clinical determinants of contralateral prophylactic mastectomy,” JAMA Surgery, vol. 149, no. 6, pp. 582–589, 2014. View at Publisher · View at Google Scholar
  57. A. Abbott, N. Rueth, S. Pappas-Varco, K. Kuntz, E. Kerr, and T. Tuttle, “Perceptions of contralateral breast cancer: an overestimation of risk,” Annals of Surgical Oncology, vol. 18, no. 11, pp. 3129–3136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Beesley, C. Holcombe, S. L. Brown, and P. Salmon, “Risk, worry and cosmesis in decision-making for contralateral risk-reducing mastectomy: analysis of 60 consecutive cases in a specialist breast unit,” The Breast, vol. 22, no. 2, pp. 179–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. J. A. Murphy, T. D. Milner, and J. M. O'Donoghue, “Contralateral risk-reducing mastectomy in sporadic breast cancer,” The Lancet Oncology, vol. 14, no. 7, pp. e262–e269, 2013. View at Publisher · View at Google Scholar · View at Scopus